Navigation Links
Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder
Date:1/26/2012

ts for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com/.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products, product candidates or partnered products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products, product candidates or partnered products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
2. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
5. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
6. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
7. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  Haemonetics Corporation (NYSE: HAE ) ... of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation (NASDAQ: ... medical devices currently manufactured in Braintree ... of integrated manufacturing solutions, components, products and repair, ...
(Date:6/19/2013)... Dr. Davis Lee , CMIO for PIH Health ... 2013 AMDIS Award, a prestigious recognition saluting excellence and ... "On behalf of Allscripts, I,d like to congratulate Dr. ... efforts to improve patient care and population health," said ... Officer of Allscripts. "We are committed to our partnership ...
(Date:6/19/2013)... , June 19, 2013 The American Association ... from Maryland , announced today the filing ... Washington, D.C. , asking that the scheduled ... for durable medical equipment (DME) be stopped because of serious ... Health and Human Services (HHS) Secretary Kathleen Sebelius ...
Breaking Medicine Technology:Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5
... After Ozarelix Was Maintained For ... Up To Six Months, ... Thereafter, IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ... Company,s drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the ...
... Hosts Key Investigator Meeting for European Participants in ... 3 AGENDA Trial Targeting Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that data from ... plus chemotherapy would be,presented at the opening session ...
Cached Medicine Technology:Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 2Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 3Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 4Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 5
(Date:6/19/2013)... 19, 2013 PrettySkin4Less announces it is ... serums by top skin care manufacturer EMINENCE to ... of vitamins, minerals and active organic ingredients to promote ... many other beauty products offer. For this reason it’s ... , "I like products that do what they ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... As Januvia lawsuit ... in courts throughout the U.S., Bernstein Liebhard LLP notes ... held a meeting to discuss the safety of Januvia ... According to a June 12th report from Bloomberg.com, the ... Januvia and similar drugs, following a recent study that ...
(Date:6/19/2013)... is believed to be the largest follow-up record of ... a movement disorder that can cause crippling muscle ... success rates and lasting benefits. , Michele Tagliati, MD, ... Medical Center,s Department of Neurology, and Ron L. Alterman, ... Israel Deaconess Medical Center in Boston, published the study ...
(Date:6/19/2013)... study reveals significant disparities between minority and white ... treatment programs. Moreover, these disparities vary widely from ... that for most states there,s something amiss," says ... biostatistics. "There are strong racial and ethnic disparities ... abuse treatment programs successfully, and those disparities are ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... PharmaTech (Cayman) Inc.,(NYSE: WX ), a leading ... with operations in China and the,United States, today announced ... WuXi PharmaTech Board of Directors. , ... Dr. Ge Li, WuXi,s Chairman and Chief ...
... Receptors and Cell Signaling at UH and MethodistHOUSTON, Feb. ... of a $5.5 million grant to the University ... (ETF). As a result of the ETF grant, UH ... to carry out laboratory research and to create next-generation ...
... today for the event to take place November 21-22 ... 5 The Leukemia & Lymphoma Society (LLS) and ... officials, announcement today granting the two organizations permission to ... November 21-22, 2009. The event, Women,s Running ...
... W.Va., Feb. 5 ReBuilder Medical Technologies, Inc. (Pink ... treatments for diabetic peripheral neuropathy and ... increase in sales for the month of January. (Logo: ... appear to be recession proof and this monthly sales ...
... unemployment rate facing Americans with disabilities , WASHINGTON, Feb. ... the first time, release employment and unemployment data on ... information will assist the nation in understanding how changing ... it is widely believed that this group typically faces ...
... February 5, 2009 Narcotics have an irreversible effect ... illness, according to Dr. Stphane Potvin of the Universit ... Louis-H Lafontaine Hospital. , According to his research, ... suffer from drug addiction. The study has shown that ...
Cached Medicine News:Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 2Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 2Health News:Internationally Acclaimed Researcher Joins UH Faculty 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 4Health News:Internationally Acclaimed Researcher Joins UH Faculty 5Health News:Internationally Acclaimed Researcher Joins UH Faculty 6Health News:The Leukemia & Lymphoma Society and Women's Running Magazine Join Forces to Launch New All-Women Half Marathon in St. Petersburg 2Health News:ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09 2Health News:U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6 2
... is an FDA approved rapid ... blood test used to aid ... infection. This CLIA waived test, ... antibodies to HIV-1, requires only ...
... The Acceava Mononucleosis test provides ... Mononucleosis with a simple procedure that ... Side-by-side evaluations with competitive products will ... These attributes enable you to deliver ...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
... Influenza A+B test allows for the ... A and type B antigens directly ... nasal aspirate specimens. The test is ... rapid differential diagnosis of acute influenza ...
Medicine Products: